Immune-Related Adverse Events: A Case-Based Approach

Immune-Related Adverse Events: A Case-Based Approach

Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with...

Full description

Bibliographic Details
Main Authors:	Caoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-06-01
Series:	Frontiers in Oncology
Subjects:	immune checkpoint inhibitors immune-related adverse events immunotherapy immune-related toxicities management
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00530/full

Similar Items

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study
by: Liz Jamieson, et al.
Published: (2020-08-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events
by: Ryan Holstead, et al.
Published: (2021-12-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Management of immune-related adverse events in patients treated with immune checkpoint inhibitors– Rheumatology point of view
by: Ho Cheuk Man, et al.
Published: (2018-12-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
by: Anca Bobircă, et al.
Published: (2021-06-01)

Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
by: Yi-He Liu, et al.
Published: (2019-12-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021-08-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
by: Lea Daniello, et al.
Published: (2021-06-01)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
by: Tao Ouyang, et al.
Published: (2021-05-01)

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
by: Kendall F. Moseley, et al.
Published: (2018-10-01)

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
by: Xiaoxiang Zhou, et al.
Published: (2020-04-01)

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
by: Marcus A. Couey, et al.
Published: (2019-07-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors
by: Maria-Carlota Londoño, et al.
Published: (2020-11-01)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
by: N. Shah, et al.
Published: (2019-09-01)

Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events
by: Bei Tan, et al.
Published: (2021-06-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
by: Hanping Wang, et al.
Published: (2020-01-01)

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
by: Gerard Milano, et al.
Published: (2021-01-01)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
by: Koji Haratani, et al.
Published: (2020-04-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
by: Iivanainen, S., et al.
Published: (2022)

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
by: Guacimara Ortega Sanchez, et al.
Published: (2018-09-01)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
by: Busra Isik, et al.
Published: (2021-04-01)